Attenzione: i dati modificati non sono ancora stati salvati. Per confermare inserimenti o cancellazioni di voci è necessario confermare con il tasto SALVA/INSERISCI in fondo alla pagina
IRIS
In an international cohort of 279 patients with hypoxemic influenza pneumonia, we identified 13 patients (4.6%) with autoantibodies neutralizing IFN-alpha and/or -omega, which were previously reported to underlie 15% cases of life-threatening COVID-19 pneumonia and one third of severe adverse reactions to live-attenuated yellow fever vaccine.Autoantibodies neutralizing type I interferons (IFNs) can underlie critical COVID-19 pneumonia and yellow fever vaccine disease. We report here on 13 patients harboring autoantibodies neutralizing IFN-alpha 2 alone (five patients) or with IFN-omega (eight patients) from a cohort of 279 patients (4.7%) aged 6-73 yr with critical influenza pneumonia. Nine and four patients had antibodies neutralizing high and low concentrations, respectively, of IFN-alpha 2, and six and two patients had antibodies neutralizing high and low concentrations, respectively, of IFN-omega. The patients' autoantibodies increased influenza A virus replication in both A549 cells and reconstituted human airway epithelia. The prevalence of these antibodies was significantly higher than that in the general population for patients <70 yr of age (5.7 vs. 1.1%, P = 2.2 x 10(-5)), but not >70 yr of age (3.1 vs. 4.4%, P = 0.68). The risk of critical influenza was highest in patients with antibodies neutralizing high concentrations of both IFN-alpha 2 and IFN-omega (OR = 11.7, P = 1.3 x 10(-5)), especially those <70 yr old (OR = 139.9, P = 3.1 x 10(-10)). We also identified 10 patients in additional influenza patient cohorts. Autoantibodies neutralizing type I IFNs account for similar to 5% of cases of life-threatening influenza pneumonia in patients <70 yr old.
Autoantibodies against type I IFNs in patients with critical influenza pneumonia
Zhang, Qian;Pizzorno, Andrés;Miorin, Lisa;Bastard, Paul;Gervais, Adrian;Le Voyer, Tom;Bizien, Lucy;Manry, Jeremy;Rosain, Jérémie;Philippot, Quentin;Goavec, Kelian;Padey, Blandine;Cupic, Anastasija;Laurent, Emilie;Saker, Kahina;Vanker, Martti;Särekannu, Karita;Abel, Laurent;Aiuti, Alessandro;Al-Muhsen, Saleh;Al-Mulla, Fahd;Anderson, Mark S.;Andreakos, Evangelos;Arias, Andrés A.;Baris Feldman, Hagit;Belot, Alexandre;Biggs, Catherine M.;Bogunovic, Dusan;Bolze, Alexandre;Bondarenko, Anastasiia;Bousfiha, Ahmed A.;Brodin, Petter;Bryceson, Yenan;Bustamante, Carlos D.;Butte, Manish J.;Casari, Giorgio;Christodoulou, John;Condino-Neto, Antonio;Constantinescu, Stefan N.;Cooper, Megan A.;Dalgard, Clifton L.;Desai, Murkesh;Drolet, Beth A.;El Baghdadi, Jamila;Espinosa-Padilla, Sara;Fellay, Jacques;Flores, Carlos;Fragkou, Paraskevi C.;Franco, José Luis;Froidure, Antoine;Galani, Ioanna Evdokia;Gregersen, Peter K.;Grimbacher, Bodo;Haerynck, Filomeen;Hagin, David;Halwani, Rabih;Hammarström, Lennart;Heath, James R.;Henrickson, Sarah E.;Hsieh, Elena W. Y.;Husebye, Eystein;Imai, Kohsuke;Itan, Yuval;Jarvis, Erich D.;Karamitros, Timokratis;Kisand, Kai;Koltsida, Ourania;Ku, Cheng-Lung;Lau, Yu-Lung;Ling, Yun;Lucas, Carrie L.;Maniatis, Tom;Mansouri, Davood;Maródi, László;Meyts, Isabelle;Milner, Joshua D.;Mironska, Kristina;Mogensen, Trine H.;Morio, Tomohiro;Ng, Lisa F. P.;Notarangelo, Luigi D.;Novelli, Antonio;Novelli, Giuseppe;O'Farrelly, Cliona;Okada, Satoshi;Okamoto, Keisuke;Ozcelik, Tayfun;Pan-Hammarström, Qiang;Pape, Jean W.;Perez de Diego, Rebeca;Perlin, David S.;Pesole, Graziano;Planas, Anna M.;Prando, Carolina;Pujol, Aurora;Quintana-Murci, Lluis;Ramaswamy, Sathishkumar;Rapti, Vasiliki;Renia, Laurent;Resnick, Igor;Rodríguez-Gallego, Carlos;Rovina, Nikoletta;Sancho-Shimizu, Vanessa;Sediva, Anna;Seppänen, Mikko R. J.;Shahrooei, Mohammed;Shcherbina, Anna;Slaby, Ondrej;Snow, Andrew L.;Soler-Palacín, Pere;Spaan, András N.;Tancevski, Ivan;Tangye, Stuart G.;Abou Tayoun, Ahmad;Temel, Şehime Gülsün;Tsiodras, Sotirios;Turvey, Stuart E.;Uddin, K. M. Furkan;Uddin, Mohammed J.;van de Beek, Diederik;Vinh, Donald C.;von Bernuth, Horst;Wauters, Joost;Zatz, Mayana;Zawadzki, Pawel;Su, Helen C.;Casanova, Jean-Laurent;Morel, Pascal;Richard, Pascale;Bonneaudeau, Brigitte;Cannet, Dorothée;Gallian, Pierre;Jeanne, Michel;Perroquin, Magali;Hamzeh-Cognasse, Hind;Cognasse, Fabrice;Tiberghien, Pierre;Nadif, Rachel;Goldberg, Marcel;Ozguler, Anna;Henny, Joseph;Lemonnier, Sylvie;Coeuret-Pellicer, Mireille;Le Got, Stéphane;Zins, Marie;Tzourio, Christophe;Debette, Stéphanie;Dufouil, Carole;Soumaré, Aïcha;Lachaize, Morgane;Fievet, Nathalie;Flaig, Amandine;Martin, Fernando;Mehlal-Sedkaoui, Souad;Sallette, Jérôme;Hernu, Romain;Lina, Bruno;Schwebel, Carole;Wroblewski, Isabelle;Morand, Patrice;Souweine, Bertrand;Boeuf, Benoit;Peigue-Lafeuille, Helene;Darmon, Michael;Patural, Hugues;Pozzetto, Bruno;Quenot, Jean Pierre;Colomb, Benoit;Pothier, Pierre;Belot, Alexandre;Abad Arranz, Maria;Aguilar Guisado, Manuela;Escoresca Ortega, Ana;Gallardo Ríos, Rafaela;Merino Díaz, Laura;Del Mar Muñoz Garcia, Maria;Ramírez Duque, Nieves;Romero Vázquez, Gloria María;Sánchez Cordero, Maria Jose;Salamanca Rivera, Celia;Niubó, Jordi;Rombauts, Alexander;Navarrete, Nicolás;Romero Oraa, Laura;Palomo, Virginia;García-Salum, Tamara;Ferres, Marcela;Le Corre, Nicole;Sánchez-Céspedes, Javier;Balsera-Manzanero, María;Carratala, Jordi;Retamar-Gentil, Pilar;Abelenda-Alonso, Gabriela;Valiente, Adoración;Tiberghien, Pierre;Zins, Marie;Debette, Stéphanie;Meyts, Isabelle;Haerynck, Filomeen;Castagnoli, Riccardo;Notarangelo, Luigi D.;Gonzalez-Granado, Luis I.;Dominguez-Pinilla, Nerea;Andreakos, Evangelos;Triantafyllia, Vasiliki;Rodríguez-Gallego, Carlos;Solé-Violán, Jordi;Ruiz-Hernandez, José Juan;Rodríguez de Castro, Felipe;Ferreres, José;Briones, Marisa;Wauters, Joost;Vanderbeke, Lore;Feys, Simon;Kuo, Chen-Yen;Lei, Wei-Te;Ku, Cheng-Lung;Tal, Galit;Etzioni, Amos;Hanna, Suhair;Fournet, Thomas;Casalegno, Jean-Sebastien;Queromes, Gregory;Argaud, Laurent;Javouhey, Etienne;Rosa-Calatrava, Manuel;Cordero, Elisa;Aydillo, Teresa;Medina, Rafael A.;Kisand, Kai;Puel, Anne;Jouanguy, Emmanuelle;Abel, Laurent;Cobat, Aurélie;Trouillet-Assant, Sophie;García-Sastre, Adolfo;Casanova, Jean-Laurent;null, null;null, null;null, null;null, null;null, null;null, null;null, null
2022-01-01
Abstract
In an international cohort of 279 patients with hypoxemic influenza pneumonia, we identified 13 patients (4.6%) with autoantibodies neutralizing IFN-alpha and/or -omega, which were previously reported to underlie 15% cases of life-threatening COVID-19 pneumonia and one third of severe adverse reactions to live-attenuated yellow fever vaccine.Autoantibodies neutralizing type I interferons (IFNs) can underlie critical COVID-19 pneumonia and yellow fever vaccine disease. We report here on 13 patients harboring autoantibodies neutralizing IFN-alpha 2 alone (five patients) or with IFN-omega (eight patients) from a cohort of 279 patients (4.7%) aged 6-73 yr with critical influenza pneumonia. Nine and four patients had antibodies neutralizing high and low concentrations, respectively, of IFN-alpha 2, and six and two patients had antibodies neutralizing high and low concentrations, respectively, of IFN-omega. The patients' autoantibodies increased influenza A virus replication in both A549 cells and reconstituted human airway epithelia. The prevalence of these antibodies was significantly higher than that in the general population for patients <70 yr of age (5.7 vs. 1.1%, P = 2.2 x 10(-5)), but not >70 yr of age (3.1 vs. 4.4%, P = 0.68). The risk of critical influenza was highest in patients with antibodies neutralizing high concentrations of both IFN-alpha 2 and IFN-omega (OR = 11.7, P = 1.3 x 10(-5)), especially those <70 yr old (OR = 139.9, P = 3.1 x 10(-10)). We also identified 10 patients in additional influenza patient cohorts. Autoantibodies neutralizing type I IFNs account for similar to 5% of cases of life-threatening influenza pneumonia in patients <70 yr old.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11586/464458
Attenzione
Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo
Citazioni
21
32
32
social impact
Conferma cancellazione
Sei sicuro che questo prodotto debba essere cancellato?
simulazione ASN
Il report seguente simula gli indicatori relativi alla propria produzione scientifica in relazione alle soglie ASN 2023-2025 del proprio SC/SSD. Si ricorda che il superamento dei valori soglia (almeno 2 su 3) è requisito necessario ma non sufficiente al conseguimento dell'abilitazione. La simulazione si basa sui dati IRIS e sugli indicatori bibliometrici alla data indicata e non tiene conto di eventuali periodi di congedo obbligatorio, che in sede di domanda ASN danno diritto a incrementi percentuali dei valori. La simulazione può differire dall'esito di un’eventuale domanda ASN sia per errori di catalogazione e/o dati mancanti in IRIS, sia per la variabilità dei dati bibliometrici nel tempo. Si consideri che Anvur calcola i valori degli indicatori all'ultima data utile per la presentazione delle domande.
La presente simulazione è stata realizzata sulla base delle specifiche raccolte sul tavolo ER del Focus Group IRIS coordinato dall’Università di Modena e Reggio Emilia e delle regole riportate nel DM 589/2018 e allegata Tabella A. Cineca, l’Università di Modena e Reggio Emilia e il Focus Group IRIS non si assumono alcuna responsabilità in merito all’uso che il diretto interessato o terzi faranno della simulazione. Si specifica inoltre che la simulazione contiene calcoli effettuati con dati e algoritmi di pubblico dominio e deve quindi essere considerata come un mero ausilio al calcolo svolgibile manualmente o con strumenti equivalenti.